1. Home
  2. AXR vs CGTX Comparison

AXR vs CGTX Comparison

Compare AXR & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo AMREP Corporation

AXR

AMREP Corporation

HOLD

Current Price

$28.78

Market Cap

110.8M

Sector

Real Estate

ML Signal

HOLD

Logo Cognition Therapeutics Inc.

CGTX

Cognition Therapeutics Inc.

HOLD

Current Price

$1.15

Market Cap

94.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AXR
CGTX
Founded
1961
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Homebuilding
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
110.8M
94.5M
IPO Year
2010
2021

Fundamental Metrics

Financial Performance
Metric
AXR
CGTX
Price
$28.78
$1.15
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$3.33
AVG Volume (30 Days)
7.6K
573.4K
Earning Date
06-23-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
89.60
N/A
EPS
1.68
N/A
Revenue
$12,831,000.00
N/A
Revenue This Year
$12.43
N/A
Revenue Next Year
$4.48
N/A
P/E Ratio
$17.22
N/A
Revenue Growth
N/A
N/A
52 Week Low
$17.60
$0.22
52 Week High
$29.00
$3.83

Technical Indicators

Market Signals
Indicator
AXR
CGTX
Relative Strength Index (RSI) 69.19 51.98
Support Level $20.58 $1.00
Resistance Level N/A $1.19
Average True Range (ATR) 1.09 0.07
MACD 0.12 0.01
Stochastic Oscillator 90.80 75.00

Price Performance

Historical Comparison
AXR
CGTX

About AXR AMREP Corporation

Amrep Corp through its subsidiaries is engaged in the Real estate business. Its activities include land sales and lease activities, which involve obtaining approvals and selling both developed and undeveloped lots to homebuilders, commercial users, and others, as well as investments in commercial and investment properties. The Company accounts for land sales, home sales, and other revenues. Its operating segments include Land development and Homebuilding. The firm generates a majority of its revenue from the Land development segment. Geographically, all the activities are carried out throughout the United States.

About CGTX Cognition Therapeutics Inc.

Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.

Share on Social Networks: